Next, the group developed a bispecific therapeutic antibody with a low affinity for TfR and a high affinity for the enzyme β-secretase (BACE1), an Alzheimer’s disease drug target. Here, BACE1 is linked to early-onset autosomal dominant Alzheimer disease.